Showing 4501-4510 of 5771 results for "".
- GSK, Vir Biotechnology Move Anti-SARS-CoV-2 Monoclonal Antibody Into Phase 3https://modernod.com/news/gsk-vir-biotechnology-move-anti-sars-cov-2-monoclonal-antibody-into-phase-3/2478385/GlaxoSmithKline and partner Vir Biotechnology announced that the COMET-ICE study evaluating VIR-7831 as an early treatment for COVID-19 patients deemed to be at high risk of hospitalization will proceed into phase 3 testing, with preliminary results coming possibly before the end of this year. Th
- Zeiss Partners With Microsoft for Better Patient Care Through Data-Driven Health Carehttps://modernod.com/news/zeiss-partners-with-microsoft-for-better-patient-care-through-data-driven-health-care/2478383/Zeiss Group and Microsoft announced a multi-year strategic partnership to accelerate Zeiss’ transformation into a digital services provider that is embracing a cloud-first approach. By standardizing its equipment and processes on Microsoft Azure as its preferred cloud platform, Zeiss will b
- John Weiss Launches the Merilas 810 Shortpulse Laser in the UKhttps://modernod.com/news/john-weiss-launches-the-merilas-810-shortpulse-laser-in-the-uk/2478380/John Weiss & Son has announced the launch of the Merilas 810 shortpulse laser in the UK. The Merilas 810 shortpulse laser provides glaucoma and retina treatments and offers new laser therapy for advanced and end-stage glaucoma. The system offers Transscleral Cyclophotocoagulation (TSCP
- Tarsus Releases Data from Io and Europa Trials for TP-03 to Treat Demodex Blepharitis and Begins Phase 2b/3 Saturn-1 Trialhttps://modernod.com/news/tarsus-releases-data-from-io-and-europa-trials-for-tp-03-to-treat-demodex-blepharitis-and-begins-phase-2b-3-saturn-1-trial/2478374/Tarsus Pharmaceuticals announced data from its phase 2 trials, Io (a Phase 2a, single-arm open-label trial) and Europa (a Phase 2b, randomized vehicle-controlled trial), evaluating the safety and efficacy of TP-03, a novel ophthalmic therapeutic being developed for t
- New Dates Set for Vision Expo East 2021https://modernod.com/news/new-dates-for-vision-expo-east-2021/2478371/The Vision Council and Reed Exhibitions, organizers of Vision Expo, announced that Vision Expo East 2021, originally scheduled to take place from March 18–21, will now take place May 25–28, 2021 (Education: May 25–28; Exhibition: May 26–28) at the Javits Center in New York City. The date change r
- Sun Ophthalmics to Present E-Posters at AAOpthttps://modernod.com/news/sun-ophthalmics-to-present-e-posters-at-aaopt/2478370/Sun Ophthalmics announced that is will be present several e-posters at the upcoming virtual AAOpt meeting being held this week. Author Presentation October 7, 4-6 pm, Session: Anterior Segment I Toyos M, Shen Lee B, Schechter B, Ogundele A, Gupta P, K
- Tarsius Pharma Achieves Positive Results in Proof of Concept Study for TRS01 Targeting Uveitishttps://modernod.com/news/tarsius-pharma-achieves-positive-results-in-proof-of-concept-study-for-trs01-targeting-uveitis/2478367/Tarsius Pharma announced that the GADOT 20/20 trial of its novel TRS01 drug for treating active anterior noninfectious uveitis, demonstrated significant improvement in critical measures such as Anterior Chamber Cells, pain reduction and increased visual acuity. The GADOT 20/20 trial was a
- New Phase 3 Analysis Demonstrates Beovu Showed Improvement in BCVA in Wet AMD Patients With Early Persistent Fluidhttps://modernod.com/news/new-phase-3-analysis-demonstrates-beovu-showed-improvement-in-bcva-in-wet-amd-patients-with-early-persistent-fluid/2478364/Novartis announced that results of two new post-hoc analyses of the phase 3 HAWK and HARRIER clinical trials in wet age-related macular degeneration (AMD) were presented at the Euretina 2020 virtual congress. The first analysis demonstrated fewer Beovu (brolucizumab) patients had early per
- Eyevensys Receives FDA Orphan Drug Designation for EYS611 for Treatment of Retinitis Pigmentosahttps://modernod.com/news/eyevensys-receives-fda-orphan-drug-designation-for-eys611-for-treatment-of-retinitis-pigmentosa/2478365/Eyevensys announced that the FDA has granted an orphan-drug designation for EYS611 for the treatment of retinitis pigmentosa (RP). Eyevensys is developing EYS611, a DNA plasmid that encodes for the human transferrin protein, to benefit patients diagnosed with RP, as well as other degenerat
- Kodiak Sciences Treats First Patients in Three Phase 3 Studies of KSI-301 for Retinal Diseaseshttps://modernod.com/news/kodiak-sciences-treats-first-patients-in-three-phase-3-studies-of-ksi-301-for-retinal-diseases/2478361/Kodiak Sciences announced that the first patients have been treated in the randomized, double-masked GLEAM, GLIMMER, and BEACON studies, three pivotal phase 3 studies of KSI-301, Kodiak’s anti-VEGF antibody biopolymer conjugate, in treatment-naïve patients with diabetic macular edema (GLEAM